User-friendly instruments for researchers in immunology
Cell Avidity
Cell avidity is the total intercellular force between multiple parallel interactions. The selection of the most effective therapeutic antibody depends on the Avidity between NK cells and cancer cells. The vital bridges between both cell types are antibodies.
The better these bispecific antibodies function as bridges, the more effectively NK cells and other T-cells can target and eliminate cancer cells. Testing the avidity of the antibody against NK cells and tumor cells is essential for maximizing therapeutic efficacy. The ability to determine the avidity of NK cells binding to cancer cells through therapeutic antibodies is a standout application of the CellVysion.
CellVysion
The CellVysion system identifies the antibody that binds to cancer cells with the perfect strength within an optimal range following a Plug & Play measurement method, which enables us to get all information available after one single run. These measurements play a key role in validating targets in therapeutic and research solutions. This will lead to better treatments for immuno-cancerous and infectious diseases.
The CellVysion: antibody-cell avidity, a crucial target validation step in the development of immuno-oncology and CAR-T therapies. The backbone is based on our patented gradient technology. By validating the therapeutic targets in an early phase, our system significantly contributes to the Likelihood of Acceptance (LOA) in clinical trials, leading to improved immuno-therapies. We have completed external field studies with Sanquin and Medlon/UT.
